About Us

Turning neurodisorder research into marketable products needs to happen faster. NNF focuses on accelerating time to market for much needed drugs, diagnostics and other medical products for patients with serious neurological disorders including autism, epilepsy and schizophrenia. Venture capital and philanthropy are complementary. Each seeks to identify and nurture exciting innovation. Both hope to realize gains in the advancement of medical knowledge. By combining venture capital and philanthropy, NNF aims to close the gap between innovative research that can lead to ground-breaking products and the companies that bring products to market.

Our initial focus on autism, epilepsy and schizophrenia allows us to leverage the new scientific commonality between various conditions once thought to be unrelated. Shared genetic and biochemical pathways give rise to distinctive and potentially overlapping clinical conditions. Basic innovative research is already generating novel insights and innovative technology is waiting to be translated into marketable products. The traditional actors who translate the research into products, the early stage VCs who finance start-up biotechs, are disappearing. As a not-for-profit organization, all investment returns will be reinvested and deployed to support additional projects and novel research to become products that can make a difference.

NNF bridges the gap between innovative research and ground-breaking products.

Identify

We identify new therapeutics and diagnostics for patients with serious neurological disorders including autism, epilepsy and schizophrenia.






Invest

We invest in companies or form companies that are translating research into products. By bridging the gap between research and product development, we help these companies become attractive to later stage VCs and Pharma who can take them to market.



Partner

We work in partnership with both research institutions and commercial organizations.










Some numbers...

  • 1 in 100 Americans with autism, schizophrenia or epilepsy
  • 1 in 68 children with autism
  • >$1 Trillion The projected 2025 economic cost to individuals, care givers and society for these neurodisorders
  • >$0.5 Billion spent on research
  • >50% reduction in neurology/psychiatric R&D venture funding over the last decade



Our Investment Approach

Collaborative

We are building a network of universities, entrepreneurs, foundations, angel investors, early-stage investors, and pharmaceutical and biotech companies. We work with all stakeholders to meet our goals. To find out more and join our network – click here





Experienced

Our team and advisors have deep biomedical industry knowledge, including bringing scores of drugs and medical products to market, running clinical trials, and founding and growing new businesses.







Hands-on

We are active managers in our investments. We leverage the experience and expertise of our team and advisors to work closely with our investments and to enable their growth and success.







Flexible

Our investments include traditional product start-ups and platform technology companies, as well as project financing for single assets. We have identified projects ready for investment right now from $250,000 to $5 million. Donate and we can put your money to work right now.




Network of Partners


If you’d like to join our network of partners, please contact us.

Our Team

Executive

  • Sandra Panem

    Sandra
    Panem

    President

    Bio
  • Brian Horsburgh

    Brian
    Horsburgh

    Treasurer & Secretary

    Bio
  • Anika Heavener

    Anika
    Heavener

    Head, Bussiness Dev.

    Bio
  • George Sassy

    George
    Sassy

    Head, Social Media

    Bio

Board Trustees

  • Peder Jensen

    Peder
    Jensen

    Board Trustee

    Bio
  • Jane Jablons

    Jane
    Jablons

    Board Trustee

    Bio
  • Stefan D. Abrams

    Stefan D.
    Abrams

    Board Trustee

    Bio
  • Marina Bozilenko

    Marina
    Bozilenko

    Board Trustee

    Bio
  • Michele Kong, M.D.

    Michele
    Kong, MD

    Board Trustee

    Bio

Scientific Advisory Board (under formation)

  • Richard Whitley

    Richard
    Whitley, MD

    Board Chair

    Bio
  • Dan Smith

    Dan
    Smith, PhD

    Board Member

    Bio
  • Kevin Pelphrey

    Kevin
    Pelphrey, PhD

    Board Member

    Bio
  • Deborah Hirtz

    Deborah
    Hirtz, MD

    Board Member

    Bio
  • Rajesh Ranganathan

    Rajesh Ranganathan,
    PhD

    Scientific Advisor

    Bio

Business Advisory Board (under formation)

  • Tierney Saccavino

    Tierney
    Saccavino

    Bio
  • Paul Thurk

    Paul
    Thurk

    Bio

Contact Us

NeuroNetworks Fund
c/o Kelley Drye Warren
101 Park Ave - 30th Floor
New York, NY 10178

info@neuronetworksfund.org